◆英語タイトル：Global Mastopexy Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)
	◆商品コード：MOR23MAC048 ◆発行会社（リサーチ会社）：Mordor Intelligence ◆発行日：2023年1月23日 ◆ページ数：115 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：アメリカ、カナダ、メキシコ、イギリス、ドイツ、フランス、スペイン、イタリア、インド、日本、中国、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン ◆産業分野：医療

The Mastopexy market studied is expected to grow with an estimated CAGR of 5.7% over the forecast period (2022-2027).

As the COVID-19 pandemic progressed with new strains, the safety of ablative resurfacing lasers, micro-needling, and dermatological surgery procedures also seemed to be unsafe. Additionally, the slowing economy and reduced discretionary spending discourage customers from undergoing expensive cosmetic treatments, thus imposing practical restrictions. The Plastic Surgery Statistics Report from the year, 2020 states that a total population of 87,051 patients underwent mastopexy surgery in 2020. Therefore the preference for aesthetic surgeries among the global population is expected to drive the growth of the market during the pandemic period.

The rising female geriatric population and growing demands for aesthetic procedures are estimated to drive market growth during the forecast period. Increased healthcare expenditures and the growing demands for outpatient surgeries are boosting market growth. Additionally, the increasing product launches are expected to contribute to the growth of the market. For, Instance, In May 2021, GC Aesthetics Inc. launched its next generation of breast implants, PERLE. PERLE is a highly innovative line of smooth breast implants that features proprietary surface technology, GCA’s industry-leading gel technology, and an enhanced version of the safety features that have underpinned GCA’s long-term excellent safety record. In February 2021, Galderma received the approval of RESTYLANE DEFYNE by the United States Food and Drug Administration for the augmentation and correction of mild to moderate chin retrusion for adults. However, factors such as the high cost of mastopexy followed by complications of the surgery are estimated to restrain the market growth during the forecast period.

Mastopexy Market Trends

Full Mastopexy Segment is Expected to Dominate the Market over the Forecast Period

Based on technique, the full mastopexy segment held a majority of the market share in terms of revenue. The full mastopexy procedure is performed in cases of breast sagginess, mainly observed in older women. Mastopexy is also performed in breast cancer patients who undergo mastectomy and lumpectomy. During the procedure, the surgeons tend to remove cancerous tissues, which can lead to breast reconstruction surgery. According to the American Cancer Society, it was estimated that 287,850 new cases of invasive breast cancer would be diagnosed in the United States in 2022. The high incidence of breast cancer can thus boost market growth.

The mastopexy restores the volume and fullness of the breasts with or without the use of implants. As per the Aesthetic Society article published in April 2022, the annual statistics of breast surgical procedures in 2021, accounted for 48% growth compared to 2020. There were 365,000 breast augmentations performed in 2021. Thus, the increase in the number of breast augmentations will help to propel the demand for full mastopexy during the forecast period.

North America is projected to have a Prominent Growth Rate over the Forecast Period

North America region is the majority share contributor to the market revenue in 2021 and is expected to continue during the forecast period. Some of the factors driving regional growth include the rising demand for aesthetic procedures among women and increased disposable income. According to the American Society of Plastic Surgeons figures, new and imaginative ways to shape the bodies are been developed, with minimally invasive cosmetic operations increasing nearly 200 percent since 2000. Breast enhancement is one of the top cosmetic surgical procedures performed in the North American region. In the United States, breast cancer is one of the leading cancer types. According to Breastcancer.org, updated in January 2022, about 1 in 8 women (about 13%) will develop invasive breast cancer over their lifetime. Such prevalence of breast cancer among women is expected to drive the growth of the market.

The demand for cosmetic surgeries and procedures in the United States is very high among women, which is one of the significant factors for the growth of the mastopexy market in the region. For instance, according to the American Society of Plastic Surgeons report published in May 2020, breast augmentation was one of the top five cosmetic surgical procedures performed in 2020 in the United States. Moreover, the total number was 193,073 breast augmentation procedures in 2020. In addition, the increasing prevalence of breast cancer in North America will also complement the growth of the mastopexy market in the region. As per the GLOBOCAN 2020 report, the new breast cancer cases in the United States, Canada, and Mexico were 253,465, 28,026, and 29,929, respectively, in 2020. Therefore, North America is expected to hold a significant market share in the Mastopexy market during the forecast period.

Mastopexy Market Competitor Analysis

The mastopexy market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Allergan, Sientra, Inc,Ideal Implant Incorporated, Johnson & Johnson, Establishment Labs, POLYTECH Health & Aesthetics GmbH, RTI Surgical, Inc., Groupe Sebin SAS, Integra LifeSciences, and GC Aesthetics.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support